Market Overview

UPDATE: Goldman Sachs Raises PT to $33 on Mylan on Agila Specialties Purchase

Related MYL
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Abbott Posts Slight Q3 Beat, Narrows Outlook
Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry (Investor's Business Daily)

In a report published Thursday, Goldman Sachs reiterated its Buy rating on Mylan (NYSE: MYL) and raised its price target from $32 to $33.

Goldman Sachs reported that, “MYL announced a definitive agreement to purchase Agila Specialties, a generics injectable producer from Strides Arcolab, for $1.6 bn in cash (+$250mn potential payments; expected to close 4Q13). We update estimates on the back of a strong quarter, higher than consensus guidance (even with higher R&D), and strong growth in specialty (30% yoy), but do not include this proposed deal. Longer term on top of possible synergies, we see prospects brightening with potential for generic Advair, where MYL is very well positioned. Management reiterated its $6.00 EPS target for 2018."

Mylan shares closed at $28.57 on Wednesday.

Latest Ratings for MYL

Oct 2016Raymond JamesUpgradesMarket PerformStrong Buy
Sep 2016Leerink SwannMaintainsOutperform
Sep 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings


Related Articles (MYL)

View Comments and Join the Discussion!